Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Adaptive Biotechnologies Corporation (ADPT)
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adhc.com
Company Research
Source: GlobeNewswire
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.MRD revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, representing an increase of 54% and 46%, respectively, over the corresponding periods in 2024. Excluding MRD regulatory milestone revenue, MRD revenue for full year 2025 grew 45% over the corresponding period in 2024.clonoSEQ test volume increased 43% to approximately 30,000 tests in the fourth quarter 2025 compared to the fourt
Show less
Read more
Impact Snapshot
Event Time:
ADPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADPT alerts
High impacting Adaptive Biotechnologies Corporation news events
Weekly update
A roundup of the hottest topics
ADPT
News
- Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 [Yahoo! Finance]Yahoo! Finance
- Adaptive Biotechnologies (NASDAQ:ADPT) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle [Seeking Alpha]Seeking Alpha
- Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer [Yahoo! Finance]Yahoo! Finance
ADPT
Earnings
- 11/5/25 - Beat
ADPT
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/12/26 - Form 144
- ADPT's page on the SEC website